Nephrotic Syndrome
📧 Sign up to get email alerts when something new happens for Nephrotic Syndrome.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-14EMA Authorised: Qaialdo (spironolactone) — Lipomed GmbH
EMA has authorized Qaialdo, a spironolactone product by Lipomed GmbH, for several conditions including edema, heart failure, liver cirrhosis…
-
EMA approval · 2026-03-24EMA Authorised: Qaialdo (spironolactone) — Lipomed GmbH
Qaialdo is a spironolactone product by Lipomed GmbH that has been authorized in the EU. Indications include edema, heart failure, liver cirr…
-
FDA approval · 2026-02-05FDA Approved: BUMETANIDE — Original Application (Novadoz Pharmaceuticals LLC)
FDA approves the original application for bumetanide (generic) from Novadoz Pharmaceuticals LLC, a loop diuretic indicated for edema associa…
-
FDA approval · 2026-01-08FDA Approved: FUROSEMIDE — Original Application (Micro Labs Limited)
FDA approved the original application for furosemide from Micro Labs Limited.
-
FDA approval · 2026-01-07FDA Approved: METOLAZONE — Supplemental Application (Method Pharmaceuticals, LLC)
The FDA approved a supplemental application for METOLAZONE submitted by Method Pharmaceuticals, LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-12-22FDA Approved: FUROSCIX — Supplemental Application (scPharmaceuticals Inc.)
The FDA approved a supplemental application for FUROSCIX (furosemide injection 80 mg/10 mL) from scPharmaceuticals Inc.
-
FDA approval · 2025-11-14FDA Approved: ALDACTONE — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approves a supplemental application for Aldactone (spironolactone) from Pfizer Laboratories Div Pfizer Inc.
-
FDA approval · 2025-10-07FDA Approved: LASIX ONYU — Original Application (SQ Innovation, Inc.)
FDA approves LASIX ONYU for the same active ingredient furosemide under an Original Application by SQ Innovation, Inc. The product is now au…
-
FDA approval · 2025-09-12FDA Approved: ENBUMYST — Original Application (Corstasis USA LLC)
The FDA approves ENBUMYST (bumetanide) from Corstasis USA LLC via its Original Application (NDA219500).
-
FDA approval · 2025-09-08FDA Approved: FUROSEMIDE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for furosemide from Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc., updating/expandin…
-
FDA approval · 2025-08-06FDA Approved: FUROSEMIDE — Supplemental Application (Meitheal Pharmaceuticals Inc.)
FDA approved a supplemental application for the generic diuretic furosemide from Meitheal Pharmaceuticals Inc. under ANDA 212803.
-
FDA approval · 2025-07-25FDA Approved: SPIRONOLACTONE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approves Camber Pharmaceuticals' generic spironolactone under an original application (ANDA 217761).
-
FDA approval · 2025-07-17FDA Approved: FUROSEMIDE — Original Application (Aurobindo Pharma Limited)
FDA approves Aurobindo Pharma Limited's original ANDA for furosemide, a generic loop diuretic. The approval covers the generic product for i…
-
FDA approval · 2025-06-13FDA Approved: BUMETANIDE — Supplemental Application (Qilu Pharmaceutical Co., Ltd.)
FDA approved a supplemental application for bumetanide from Qilu Pharmaceutical Co., Ltd., authorizing the generic product's approval.
-
FDA approval · 2025-05-08FDA Approved: FUROSEMIDE — Supplemental Application (Eugia US LLC)
FDA approved a supplemental application for furosemide by Eugia US LLC under an ANDA, confirming approval of the supplement.
-
FDA approval · 2025-04-03FDA Approved: BUMETANIDE — Original Application (First Nation Group, LLC)
FDA approves bumetanide under an Original Application filed by First Nation Group, LLC (ANDA219291).
-
FDA approval · 2025-02-27FDA Approved: BUMETANIDE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' original application for bumetanide, a loop diuretic used to treat edema due to congestive heart failur…
-
FDA approval · 2025-02-21FDA Approved: SPIRONOLACTONE — Original Application (Camber Pharmaceuticals, Inc.)
The FDA approved Camber Pharmaceuticals' original application for spironolactone, establishing a generic version of the diuretic. Spironolac…
-
FDA approval · 2025-01-23FDA Approved: SPIRONOLACTONE — Original Application (Rising Pharma Holdings, Inc.)
The FDA approved the original application for spironolactone (generic) from Rising Pharma Holdings, Inc., authorizing the marketing of a gen…
-
FDA approval · 2024-12-13FDA Approved: FUROSEMIDE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' original application for furosemide, enabling a generic version of the loop diuretic to be marketed.
-
FDA approval · 2024-11-06FDA Approved: METOLAZONE — Original Application (Micro Labs Limited)
The FDA approved the generic METOLAZONE from Micro Labs Limited under an Original Application. This metolazone product is a thiazide-like di…
-
FDA approval · 2024-10-01FDA Approved: FUROSEMIDE — Supplemental Application (Phlow Corporation)
The FDA approved a supplemental application for furosemide from Phlow Corporation, authorizing an additional or revised approval for the diu…
-
FDA approval · 2024-09-19FDA Approved: HYDROCHLOROTHIAZIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for hydrochlorothiazide from Teva Pharmaceuticals USA, Inc. The approval concerns regulatory changes…
-
FDA approval · 2024-04-30FDA Approved: HYDROCHLOROTHIAZIDE — Supplemental Application (Accord Healthcare Inc.)
The FDA approved a supplemental application for hydrochlorothiazide filed by Accord Healthcare Inc. under ANDA 202556. The document does not…
-
FDA approval · 2023-10-10FDA Approved: SPIRONOLACTONE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for spironolactone by Mylan Pharmaceuticals Inc., updating the approval for this generic diuretic. T…